Sirtuin-2 Activity is Required for Glioma Stem Cell Proliferation Arrest but not Necrosis Induced by Resveratrol

Stem Cell Reviews and Reports

Volumn 10, Issue 1, 2014, Pages 103-113

  Sayd, Salwa ^a,b   Thirant, Cécile ^a   El Habr, Elias A ^a   Lipecka, Joanna ^a   Dubois, Luiz Gustavo ^a   Bogeas, Alexandra ^a   Tahiri Jouti, Nadia ^b   Chneiweiss, Hervé ^a,c   Junier, Marie Pierre ^a,c  

^a INSERM   (France)

^b Laboratory of Genetics and Molecular Pathology Medical School of Casablanca   (Morocco)

^c CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

Cancer stem cell; Necrosis; Sirtuin; tubulin

Indexed keywords

RESVERATROL; SIRT2 PROTEIN, HUMAN; SIRTUIN 2; SMALL INTERFERING RNA; STILBENE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GLIOBLASTOMA; HUMAN; METABOLISM; NECROSIS; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; NECROSIS; NEOPLASTIC STEM CELLS; RNA, SMALL INTERFERING; SIRTUIN 2; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84893742636     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-013-9465-0     Document Type: Article

References (56)

1. Stupp, R., Mason, W. P., van den Bent, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987-996.
2. Bao, S., Wu, Q., McLendon, R. E., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756-760.
3. Diehn, M., & Clarke, M. F. (2006). Cancer stem cells and radiotherapy: new insights into tumor radioresistance. Journal of the National Cancer Institute, 98(24), 1755-1757.
4. Chen, J., Li, Y., Yu, T. S., et al. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488(7412), 522-526.
5. Thirant, C., Bessette, B., Varlet, P., et al. (2011). Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS ONE, 6(1), e16375.
6. Zbinden, M., Duquet, A., Lorente-Trigos, A., et al. (2010). NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. The EMBO Journal, 29(15), 2659-2674.
7. Fareh, M., Turchi, L., Virolle, V., et al. (2012). The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell death and differentiation, 19(2), 232-244.
8. Eyler, C. E., & Rich, J. N. (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology, 26(17), 2839-2845.
9. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Research, 24(5A), 2783-2840.
10. Narita, K., Hisamoto, M., Okuda, T., & Takeda, S. (2011). Differential neuroprotective activity of two different grape seed extracts. PLoS ONE, 6(1), e14575.
11. Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2010). Resveratrol as a therapeutic agent for neurodegenerative diseases. Molecular Neurobiology, 41(2-3), 375-383.
12. Milne, J. C., Lambert, P. D., Schenk, S., et al. (2007). Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 450(7170), 712-716.
13. Vaziri, H., Dessain, S. K., NgEaton, E., et al. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107(2), 149-159.
14. Narayan, N., Lee, I. H., Borenstein, R., et al. (2012). The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature, 492(7428), 199-204.
15. Hiratsuka, M., Inoue, T., Toda, T., et al. (2003). Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochemical and Biophysical Research Communications, 309(3), 558-566.
16. Zhang, W., Murao, K., Zhang, X., et al. (2010). Resveratrol represses YKL-40 expression in human gliomaU87 cells. BMC Cancer, 10, 593.
17. Filippi-Chiela, E. C., VillodreES, Z. L. L., & Lenz, G. (2011). Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS ONE, 6(6), e20849.
18. Shu, X. H., Li, H., Sun, X. X., et al. (2011). Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS ONE, 6(11), e27484.
19. Jiang, H., Zhang, L., Kuo, J., et al. (2005). Resveratrol-induced apoptotic death in human U251 glioma cells. Molecular Cancer Therapeutics, 4(4), 554-561.
20. Lin, H., Xiong, W., Zhang, X., et al. (2011). Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncology Reports, 26(4), 925-930.
21. Lin, C. J., Lee, C. C., Shih, Y. L., et al. (2012). Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radical Biology and Medicine, 52(2), 377-391.
22. Huang, H., Lin, H., Zhang, X., & Li, J. (2012). Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Oncology Reports, 27(6), 2050-2056.
23. Silvestre, D. C., Pineda, J. R., Hoffschir, F., et al. (2011). Alternative lengthening of telomeres in human glioma stem cells. Stem Cells, 29(3), 440-451.
24. Surena, A. L., de Faria, G. P., Studler, J. M., et al. (2009). DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochimica et Biophysica Acta, 1793(2), 264-272.
25. Patru, C., Romao, L., Varlet, P., et al. (2010). CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer, 10, 66.
26. Galan-Moya, E. M., Le Guelte, A., Lima Fernandes, E., et al. (2011). Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Reports, 12(5), 470-476.
27. Thirant, C., Galan-Moya, E. M., Dubois, L. G., et al. (2012). Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells, 30(5), 845-853.
28. Lee, J., Kotliarova, S., Kotliarov, Y., et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9(5), 391-403.
29. Degenhardt, K., Mathew, R., Beaudoin, B., et al. (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 10(1), 51-64.
30. Mathew, R., Karantza-Wadsworth, V., & White, E. (2007). Role of autophagy in cancer. Nature Reviews. Cancer, 7(12), 961-967.
31. Kabeya, Y., Mizushima, N., Ueno, T., et al. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. The EMBO Journal, 19(21), 5720-5728.
32. Baur, J. A. (2010). Resveratrol, sirtuins, and the promise of a DR mimetic. Mechanisms of Ageing and Development, 131(4), 261-269.
33. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., & Verdin, E. (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Molecular Cell, 11(2), 437-444.
34. Leist, M., Single, B., Castoldi, A. F., Kühnle, S., & Nicotera, P. (1997). Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. The Journal of Experimental Medicine, 185(8), 1481-1486.
35. Athar, M., Back, J. H., Tang, X., et al. (2007). Resveratrol: a review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology, 224(3), 274-283.
36. Gagliano, N., Aldini, G., Colombo, G., et al. (2010). The potential of resveratrol against human gliomas. Anti-cancer Drugs, 21(2), 140-150.
37. Aziz, M. H., Nihal, M., Fu, V. X., Jarrard, D. F., & Ahmad, N. (2006). Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Molecular Cancer Therapeutics, 5(5), 1335-1341.
38. Michels, G., Wätjen, W., Weber, N., et al. (2006). Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Toxicology, 225(2-3), 173-182.
39. Vanamala, J., Reddivari, L., Radhakrishnan, S., & Tarver, C. (2010). Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer, 10, 238.
40. Puissant, A., Robert, G., Fenouille, N., et al. (2010). Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Research, 70(3), 1042-1052.
41. Li, J., Qin, Z., & Liang, Z. (2009). The prosurvival role of autophagy in Resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer, 9, 215.
42. Yang, Y. P., Chang, Y. L., Huang, P. I., et al. (2012). Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. Journal of Cellular Physiology, 227(3), 976-993.
43. Griguer, C. E., Oliva, C. R., Gobin, E., et al. (2008). CD133 is a marker of bioenergeticstress in human glioma. PLoS ONE, 3(11), e3655.
44. Wenzel, E., Soldo, T., Erbersdobler, H., & Somoza, V. (2005). Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Molecular Nutrition and Food Research, 49(5), 482-494.
45. Planas, J. M., Alfaras, I., Colom, H., & Juan, M. E. (2012). The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Archives of Biochemistry and Biophysics, 527(2), 67-73.
46. Hambardzumyan, D., Squatrito, M., Carbajal, E., & Holland, E. C. (2008). Glioma formation, cancer stem cells, and akt signaling. Stem Cell Reviews, 4(3), 203-210.
47. Kroemer, G., Galluzzi, L., Vandenabeele, P., et al. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death and Differentiation, 16(1), 3-11.
48. Edinger, A. L., & Thompson, C. B. (2004). Death by design: apoptosis, necrosis and autophagy. Current Opinion in Cell Biology, 16(6), 663-669.
49. Suzuki, K., & Koike, T. (2007). Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochemical and Biophysical Research Communications, 359(3), 665-671.
50. Fan, Y., Ludewig, R., & Scriba, G. K. (2009). 9-Fluorenylmethoxycarbonyl-labeled peptides as substrates in a capillary electrophoresis-based assay for sirtuin enzymes. Analytical Biochemistry, 387(2), 243-248.
51. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 317(5837), 516-519.
52. Inoue, T., Hiratsuka, M., Osaki, M., & Oshimura, M. (2007). The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle, 6(9), 1011-1018.
53. Anekonda, T. S. (2006). Resveratrol-a boon for treating Alzheimer's disease? Brain Research Reviews, 52(2), 316-326.
54. Pfister, J. A., Ma, C., Morrison, B. E., & D'Mello, S. R. (2008). Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS ONE, 3(12), e4090.
55. Liu, B., Ghosh, S., Yang, X., et al. (2012). Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metabolism, 16(6), 738-750.
56. Lin, J. N., Lin, V. C., Rau, K. M., et al. (2010). Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. Journal of Agricultural and Food Chemistry, 58(3), 1584-1592.